Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03267498 | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 40 | Sue YomOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | completed | Phase 2 | 20 | Dan ZandbergOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04031534 |
| Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma(HYPONECK) |
| completed |
| Phase 2 |
| 16 |
| Centre Henri BecquerelOTHER |
| 1 |
| Jan 2, 2026 |
| clinicaltrials |
| NCT04227509 | Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04004871 | Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 60 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04811027 | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC(TACTI-003) | completed | Phase 2 | 171 | Immutep S.A.S.INDUSTRY | 9 | Dec 11, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT04454489 | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | completed | Phase 2 | 21 | Wake Forest University Health SciencesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT02369458 | Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | completed | Phase 2 | 17 | Medical University of South CarolinaOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02882282 | Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05271604 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 42 | BioAtla, Inc.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05459129 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | completed | Phase 1 / Phase 2 | 12 | Hoffmann-La RocheINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT06521775 | An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 6 | Mayo ClinicOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT02098538 | Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03623646 | Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.(CITHARE) | completed | Phase 2 | 11 | Institut Claudius RegaudOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02795195 | Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 51 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | completed | Phase 2 | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03984357 | Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma(PLATINUM) | completed | Phase 2 | 152 | Sun Yat-sen UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04833257 | Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC | completed | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00832429 | Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | completed | Phase 1 / Phase 2 | 25 | Nektar TherapeuticsINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04552769 | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT05499065 | Real-time Margin Assessment in Head and Neck Cancer(LIGHTNING) | completed | Phase 2 | 23 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05516589 | Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC(neoCHANCE-2) | completed | Phase 2 | 40 | West China HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03274414 | A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages | completed | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03944915 | De-Escalation Therapy for Human Papillomavirus Negative Disease(DEPEND) | completed | Phase 2 | 35 | University of ChicagoOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03212469 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer(ABIMMUNE) | completed | Phase 1 / Phase 2 | 54 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT04278092 | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | completed | Phase 2 | 57 | Medical University of ViennaOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03107182 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer(OPTIMA-II) | completed | Phase 2 | 72 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04752384 | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT00381641 | Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03602911 | A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients | completed | Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04736810 | A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 28 | AkesoINDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03866967 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 130 | AkesoINDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 12, 2026source: clinicaltrials